Circulating miRNA-499 and miRNA-208b indicate cardioprotection by sevoflurane anesthesia in patients undergoing OPCABG.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13004035

Enrollment

Unknown

Registered

2013-11-21

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease

Interventions

SEVO:sevoflurane VIMA

PROP:propofol TIVA

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Off-pump CABG patients, ASA II-III grade.

Exclusion criteria

Exclusion criteria: The exclusion criteria were emergency surgery, left ventricular ejection fraction<40%, diabetes, old myocardial infarction, allergic history of anesthetics, abnormal coagulate function, contraindications of transesophageal echocardio- graphy.

Design outcomes

Primary

Measure	Time frame
microRNA499;microRNA208;	—

Countries

China

Contacts

Public ContactE Wang

Xiangya Hospital of Central South University

ewang324@sina.com+86 18874889950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026